NEW YORK (360Dx) – Hologic announced after the close of the market on Tuesday that it has completed the sale of its stake in blood screening firm Grifols for $1.85 billion.

At the time the deal was announced in December, Hologic Chairman, President, and CEO Steve MacMillan said that Grifols, while having excellent value for a non-core business, nonetheless, "was a drag on our growth" and operated in a challenging market with ongoing headwinds.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.